NantKwest
1
18M
1
0.05
1
1
- Areas of investment
Summary
In 2002 was created NantKwest, which is appeared as Corporate Investor. The main department of described Corporate Investor is located in the San Diego. The fund was located in North America if to be more exact in United States.
The typical case for the fund is to invest in rounds with 4 participants. Despite the NantKwest, startups are often financed by Lilly Ventures, Forward Ventures, DeNovo Ventures. The meaningful sponsors for the fund in investment in the same round are Wicklow Capital, Latterell Venture Partners, Forward Ventures. In the next rounds fund is usually obtained by Taiwania Capital, SalubrisBio.
The fund is generally included in less than 2 deals every year. The top activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Among the most successful fund investment fields, there are Biotechnology, Biopharma. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Viracta Therapeutics
Investments analytics
Analytics
- Total investments
- 1
- Lead investments
- 1
- Exits
- 1
- Rounds per year
- 0.05
- Investments by industry
- Therapeutics (1)
- Biopharma (1)
- Pharmaceutical (1)
- Biotechnology (1)
- Medical (1)
- Investments by region
-
- United States (1)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 14
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Viracta Therapeutics | 04 Apr 2017 | Biotechnology, Medical, Pharmaceutical, Therapeutics, Biopharma | Early Stage Venture | 18M | United States, California |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.